Biohaven price target lowered to $59 from $63 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Biohaven to $59 from $63 and keeps a Buy rating on the shares post the Q1 report. The analyst cites share dilution for the target cut. Biohaven plans to accelerate the development of BHV-1300 across additional autoantibody-mediated targets, the analyst tells investors in a research note.